Table 2 Comorbidities and complications in COVID-19 positive and non-COVID patients with myasthenia
From: Impact of COVID-19 infection among myasthenia gravis patients- a Cerner Real-World DataTM study
Co-morbidities | COVID Patients with myasthenia (n= 27) | Non-COVID Patients with myasthenia (n=64) | P-value | ||
Hypertension | 1 | 3.70% | 4 | 6.25% | 0.986 |
Diabetes mellitus | 5 | 18.52% | 6 | 9.38% | 0.384 |
Obstructive Sleep apnea | 5 | 18.52% | 12 | 18.75% | 0.979 |
Hyperlipidemia | 9 | 33.33% | 32 | 50.00% | 0.144 |
Atrial fibrillation | 3 | 11.11% | 13 | 20.31% | 0.452 |
Obesity | 0 | 0.00% | 1 | 1.56% | 0.654 |
COPD | 4 | 3.70% | 13 | 4.69% | 0.538 |
Complications | COVID Patients with myasthenia (n= 27) | Non-COVID Patients with myasthenia (n=64) | P-value | ||
Pneumonia | 13 | 48.15% | 28 | 43.75% | 0.7 |
Septic shock | 9 | 33.33% | 13 | 20.31% | 0.185 |
Acute Respiratory failure | 10 | 37.04% | 22 | 34.38% | 0.808 |
Chronic Respiratory failure | 1 | 3.70% | 3 | 4.69% | 0.725 |